SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
TGTX

Tg Therapeutics, Inc. (NASDAQ:TGTX)

US · Delayed Price · Currency is USD
Also listed: 0VGI.LHealthcare · Biotechnology
$63.34-$1.54 (-2.37%)
 
Market cap
$9.57B
Insider Score
Health Score
Analyst consensus
Listed since
May 3, 2010
Market Cap$9.57B+98.3%
Revenue (ttm)$897.76M+68.8%
Net Income$106.06M-76.3%
EPS$0.66-76.3%
Shares Out151.15M
PE Ratio85.03
Forward PE22.85
Dividendn/a
Ex-Dividend Daten/a
Volume2,087,261
Open$64.32
Previous Close$64.88
Day's Range$63.12 - $65.64
52-Week Range$26.76 - $68.03
Beta1.81
AnalystsBuy
Price Target$80.50(+27.09%)
Earnings DateFeb 25, 2027

About TGTX

Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.

Address
3020 Carrington Mill Blvd., Morrisville, NY, 27560, US
Market Cap
9.57 billion
Employees
399
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$437.65K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $78.00 (+23.1%)

2 firms rating TGTX in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Strong
From TGTX’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-2.37%
5 Days
-2.09%
1 Month
+19.06%
6 Months
+61.42%
1 Year
+98.25%

$TGTX stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in TGTX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by TGTX's directors and management

Net Shares Purchased by Insiders−5k−3k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

TGTX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

TGTX Revenue by Segment or Geography

TGTX's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New TGTX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to TGTX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in TGTX

IJRiShares Core S&P Small-Cap ETF$554.30M
IWMiShares Russell 2000 ETF$247.21M
VTIVanguard Morningstar Total Stock Market ETF$212.43M
VBVanguard Morningstar Small-Cap ETF$188.96M
XBIState Street SPDR S&P Biotech ETF$179.80M
FBTFirst Trust NYSE Arca Biotechnology Index Fund$115.77M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from TGTX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
93
News & Sentiment
20% of score
72

News check: Q3 earnings and revenue beat, raised 2026 guidance, Deloitte Fast 500 ranking, and positive analyst coverage outweigh valuation concerns.

Recent Insider Activity

Buys
0
Sells
2
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

+0.0 since Sep 15
0255075100Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 32.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 15Sep 24Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

PSCHInvesco S&P SmallCap Health Care ETF4.91%
FBTFirst Trust NYSE Arca Biotechnology Index Fund3.80%
PBEInvesco Biotechnology & Genome ETF3.18%
GRPZInvesco S&P SmallCap 600 GARP ETF2.20%
XBIState Street SPDR S&P Biotech ETF1.77%
BBPVirtus Biotech ETF1.71%
XSHQInvesco S&P SmallCap Quality ETF1.62%
RZGInvesco S&P SmallCap 600 Revenue ETF1.62%
SAWSAAM Sawgrass U.S. Small Cap Quality Growth ETF1.52%
HYPGolden Eagle Dynamic Hypergrowth ETF1.24%
JSMLJanus Henderson Small Cap Growth Alpha ETF1.15%
CTAGCalamos Timpani Active SMID Growth ETF1.14%

Weight is the stock’s share of each fund’s holdings.